World Preclinical Congress 2016 | Immunosequencing for Cancer Immunotherapy Development

CHI interviewed Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies on the utilization of high-throughput sequencing and expert bioinformatics profiling T-cell and B-cell receptors, also known as immunosequencing, to enable the development of a new generation of cancer immunotherapies. Discussion questions include: 1. Can you tell us a bit about Adaptive Biotechnologies, its origins, and where you are as a company now? 2. Can you please tell us about immunosequencing, and its applications in preclinical and clinical settings? 3. You are giving a luncheon presentation during the Cancer Immunotherapy and Combinations meeting, June 15-16, 2016 in Boston. Can you give us an idea of what you hope to convey to attendees during this lecture? 4. What challenges exist that may be overcome in the near future? What does the future of Adaptive and immunosequencing look like? For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Immunotherapy-Combinations/